Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

New EACS 2025 data show once-weekly islatravir and lenacapavir maintain HIV viral suppression for 96 weeks with no resistance ...

More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...

Merck (NYSE:MRK) reported positive results from late-stage studies on a new oral treatment which combines two drugs, ...

HIV remains a major global health issue, affecting nearly 40 million people worldwide. Current treatments, known as ...

Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...

In what may be one of the most important HIV research breakthroughs in years, scientists have discovered a strikingly ...

Community advocates, health providers and local leaders in Charleston are all joining forces Wednesday in observance of ...

This tiny nation was winning in its fight against HIV. Then Trump cut foreign aid - With the single stroke of Trump’s pen, ...